Abstract Bacillus Calmette-Guérin (BCG) is the most effective intravesical immunotherapy for
superficial bladder cancer. Although generally well tolerated, BCG-related infectious …

Bladder cancer is the sixth most common cancer in the United States, and 70% of cases are
non–muscle invasive. Intravesical bacillus Calmette-Guérin (BCG) immunotherapy …

Intravesical instillation of bacille Calmette-Guérin (BCG) effectively treats transitional cell
carcinoma of the bladder. Occasionally, BCG infection complicates such treatment. In some …

Mycobacterium tuberculosis and Mycobacterium bovis cause tuberculosis, which is
responsible for the deaths of more people each year than any other bacterial infectious …

The Mycobacterium tuberculosis complex (MTBC) consists of a group of closely related
species that differ in their epidemiological profiles, host ranges, pathogenicities, geographic …

Abstract Background Although intravesical bacille Calmette-Guérin (BCG) therapy is
accepted as an effective treatment for bladder cancer, serious complications may occur in …

We report a culture-proven case of Mycobacterium bovis vertebral osteomyelitis in a 76-year-
old man who had undergone intravesical BCG therapy for bladder cancer 7 years …

Although osteoarticular side effects of the Bacillus Calmette-Guérin (BCG) are rare
compared to the number of administrations, BCG vaccination and cancer therapy are so …

We report a 58-year-old man with spondylodiscitis by Mycobacterium bovis-BCG 3 years
after intravesical BCG treatment, and shortly after a vertebroplasty. Further examination …

Intravesical Mycobacterium bovis BCG instillation therapy is commonly used to prevent
recurrences of carcinoma in situ (CIS) and/or Ta/T1 papillary tumors of the urinary bladder …